Filipe A. Moura

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial”.

Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial

American Heart Journal(2025)10.1016/j.ahj.2025.02.022

N/A

0.453DataRank · unranked

12 citations

Nicholas Marston, Thomas A Prohaska, Veronica J. Alexander, André Zimerman, Filipe A. Moura +9 more

Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia

American Heart Journal(2025)10.1016/j.ahj.2025.03.003

N/A

0.408DataRank · unranked

10 citations

Brian A. Bergmark, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, Yu Mi Kang, Filipe A. Moura +8 more

Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers

Diabetes Obesity and Metabolism(2024)10.1111/dom.16123

N/A

0.170DataRank · unranked

2 citations

Frederick Kamanu, Stephen D. Wiviott, Robert P. Giugliano, Miriam S. Udler, Jose C. Florez +5 more

Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure

JACC. Cardiovascular imaging(2023)10.1016/j.jcmg.2023.07.014

N/A

0DataRank · unranked

63 citations

Michael H. Rosenthal, Filipe A. Moura, Sanjay Divakaran, Michael T. Osborne, Jon Hainer +5 more

Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy

Diabetes Obesity and Metabolism(2024)10.1111/dom.15798

N/A

0DataRank · unranked

2 citations

Andrea Bellavia, David D. Berg, Giorgio Melloni, Mark W. Feinberg, Lawrence A. Leiter +6 more

Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes

Diabetes Care(2023)10.2337/dc23-0492

N/A

0DataRank · unranked

14 citations

David D. Berg, Andrea Bellavia, Jamie P. Dwyer, Ofri Mosenzon, Benjamin M. Scirica +8 more

Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes

European Heart Journal(2024)10.1093/eurheartj/ehae827

N/A

0DataRank · unranked

47 citations

Amelie S. Troschel, J. Peter Marquardt, Ibrahim Hadžić, Borek Foldyna, Filipe A. Moura +10 more